Commentary: Stereotactic body radiation therapy versus surgery for stage I non-small cell lung cancer in healthy patients: Not quite there yet
- PMID: 36003466
- PMCID: PMC9390463
- DOI: 10.1016/j.xjon.2021.11.011
Commentary: Stereotactic body radiation therapy versus surgery for stage I non-small cell lung cancer in healthy patients: Not quite there yet
Figures
Comment on
- doi: 10.1016/j.xjon.2021.09.052
References
-
- Littau M.J., Freeman R., Vigneswaran W.T., Luchette F.A., Baker M.S., Raad W., et al. Comparative effectiveness of stereotactic body radiation therapy versus surgery for stage I lung cancer in otherwise healthy patients: an instrumental variable analysis. J Thorac Cardiovasc Surg Open. 2022;9:249–261. - PMC - PubMed
-
- Khorfan R., Kruser T.J., Coughlin J.M., Bharat A., Bilimoria K.Y., Odell D.D. Survival of primary stereotactic body radiation therapy compared with surgery for operable stage I/II non-small cell lung cancer. Ann Thorac Surg. 2020;110:228–234. doi: 10.1016/j.athoracsur.2020.01.073. - DOI - PMC - PubMed
-
- Chang J.Y., Senan S., Paul M.A., Mehran R.J., Louie A.V., Balter P., et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–637. doi: 10.1016/S1470-2045(15)70168-3. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
